Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metavax is a multivitamin and dietary supplement product developed by Blue Heron Pharmaceuticals, primarily marketed for the nutritional management of patients with metabolic imbalances or specific vitamin deficiencies. It is formulated as an oral tablet containing a combination of active B-vitamins, including L-methylfolate (levomefolate calcium), methylcobalamin (Vitamin B12), and pyridoxal-5-phosphate (Vitamin B6). These ingredients serve as essential cofactors in the homocysteine metabolism pathway and the methylation cycle. Metavax is often used to address conditions such as hyperhomocysteinemia or to provide nutritional support for patients with diabetic peripheral neuropathy, where impaired B-vitamin metabolism may play a role in nerve health and metabolic stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Metavax.